Eun Yang
Stock Analyst at Jefferies
(0.45)
# 4,138
Out of 5,030 analysts
35
Total ratings
31.58%
Success rate
-26.79%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATXS Astria Therapeutics | Downgrades: Hold | $30 → $13 | $12.09 | +7.53% | 3 | Oct 14, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $432.69 | -0.16% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $5.08 | +57.48% | 2 | May 14, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.55 | +170.81% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $55.03 | -40.03% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.59 | +1,661.01% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $21.75 | +24.14% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $2.13 | +228.64% | 1 | Feb 10, 2023 | |
| CVAC CureVac | Upgrades: Buy | n/a | $5.37 | - | 2 | Jan 9, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $5.80 | +331.03% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105,000 → $15,000 | $5.14 | +291,728.79% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.35 | +646.27% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $22.86 | +53.11% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $295.81 | -25.63% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $142.26 | +117.91% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $117.85 | -32.12% | 3 | Jul 11, 2017 |
Astria Therapeutics
Oct 14, 2025
Downgrades: Hold
Price Target: $30 → $13
Current: $12.09
Upside: +7.53%
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $432.69
Upside: -0.16%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $5.08
Upside: +57.48%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.55
Upside: +170.81%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $55.03
Upside: -40.03%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.59
Upside: +1,661.01%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $21.75
Upside: +24.14%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $2.13
Upside: +228.64%
CureVac
Jan 9, 2023
Upgrades: Buy
Price Target: n/a
Current: $5.37
Upside: -
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $5.80
Upside: +331.03%
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $5.14
Upside: +291,728.79%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $3.35
Upside: +646.27%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $22.86
Upside: +53.11%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $295.81
Upside: -25.63%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $142.26
Upside: +117.91%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $117.85
Upside: -32.12%